La chaîne d'options affiche les données clés des options sur actions de Lyell Immunopharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Lyell Immunopharma..

Lyell Immunopharma (NASDAQ:LYEL) Stock, Chaîne d'Options

LYELL IMMUNOPHARMA INC

Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Lyell Immunopharma Inc

WIIM

ADAP

Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) with a Buy and maintains $4.25 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

Earnings

Earnings Beats

Earnings Misses

LSTR

Landstar System Q1 EPS $0.85 Misses $0.99 Estimate, Sales $1.15B Beat $1.13B Estimate

SGMO

Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

Bridgemarq Real Estate (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BRE#TSX">BRE</a>) reported quarterly earnings of $0.20 per share. This is a 5.26 percent increase over earnings of $0.19 per share from the same period last year. The company reported $77.97 million in sales this quarter. This is a 562.62 percent increase over sales of $11.77 million the same period last year.

TSX:BRE

Bridgemarq Real Estate Q1 Adj. EPS $0.20 Up From $0.19 YoY, Sales $77.97M Up From $11.77M YoY

ITOS

Trading Halt: Halted at 7:50:00 a.m. ET - Trading Halt: Halt News Pending

Palmer Luckey, the virtual-reality prodigy who sold Oculus to Facebook for $2 billion in 2014, says that payday granted him entry to an ultra-exclusive group chat called the "B Boys Club."
What Happened: The only password to the group chat is a unicorn-level exit: founders must have sold a company for at least $1 billion. "It's all boys who have sold a company for at least $1 billion," Luckey <a href="https://www.youtube.com/watch?v=21I_3VEs0iI">told</a> Peter Diamandis on the "Moonshots" podcast. While he insists women aren't barred, none are in the thread.
That omission is striking given deals like L'Oréal's $1.2 billion purchase of IT Cosmetics from co-founder Jamie Kern Lima in 2016.
By club standards, Instagram's Kevin Systrom and Mike Krieger (<a href="https://www.benzinga.com/news/15/10/5891968/instagrams-fifth-anniversary-how-good-of-a-deal-was-this-for-facebook">sold</a> to Facebook for $1 billion in 2012) would qualify easily. So would WhatsApp's Jan Koum and Brian Acton, who <a href="https://www.benzinga.com/news/14/02/4322191/update-facebook-announces-16b-cash-stock-merger-with-whatsapp">fetched</a> $19 billion two years later. Slack co-founder Stewart Butterfield dwarfs them all, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/12/18616683/6-salesforce-analysts-react-to-slack-deal-game-changer-potential">exiting</a> to Salesforce for $27.7 billion in 2021.
See also: <a href="https://www.benzinga.com/25/05/45370909/china-rejects-us-blame-for-fentanyl-crisis-calls-tariff-penalties-unreasonable-amid-easing-trade-tensions">China Rejects US Blame For Fentanyl Crisis, Calls Tariff Penalties Unreasonable Amid Easing Trade Tensions</a>
Some of the planet's richest men, however, are stuck on read. Meta chief Mark Zuckerberg, who&#8217;s worth roughly $226 billion by Bloomberg's latest count, never actually sold Facebook, so he's out, as are Bill Gates, Sam Altman and Warren Buffett.
What To Know: Luckey, now <a href="https://www.forbes.com/profile/palmer-luckey/">valued</a> by Forbes at about $2.5 billion thanks to defense-tech startup Anduril, spends his chat time "shaming" peers into using their fortunes for more than vintage race cars.
"Guys, you have so much money. Why are you not doing what you know is the right thing to do with this capital?" he recalled messaging.
Luckey believes founders should personally build the world they envision instead of outsourcing philanthropy. Some converts are redirecting cash; others, he concedes, still prefer the fast lane. "I'm not saying everyone should become a vigilante crime fighter, but why wouldn't you use your resources to do the thing that you know needs to be done?" Luckey said.
Image via Just dance/Shutterstock
Read next: <a href="https://www.benzinga.com/news/global/25/05/45369837/piers-morgan-tears-into-pakistani-expert-who-says-isi-didnt-know-osama-bin-laden-was-living-near-military-base-all-they-had-to-do-was-get-a-pair-of-binoculars">Piers Morgan Tears Into Pakistani Expert Who Says ISI &#8216;Didn&#8217;t Know&#8217; Osama Bin Laden Was Living Near Military Base: &#8216;All They Had To Do Was Get A Pair Of Binoculars&#8217;</a>

Tech

Oculus Founder Palmer Luckey Reveals He's In An Invite-Only Group Chat With Just One Entry Rule

Kohl's intends to use the net proceeds from the sale of the Notes in a series of transactions resulting in the repayment of borrowings under its revolving credit facility. Kohl's expects to borrow under its revolving credit facility to repay all of its 4.25% notes due 2025 at maturity.

Kohl's Plans $360M Senior Secured Notes Offering Due 2030, Cites Use Of Proceeds For Debt Repayment Strategy

Telsey Advisory Group analyst Dana Telsey maintains FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) with a Market Perform and maintains $5 price target.

FIGS

Telsey Advisory Group Maintains Market Perform on FIGS, Maintains $5 Price Target

Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.04 by 380 percent. This is a 230.61 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $81.11 million which missed the analyst consensus estimate of $85.59 million by 5.23 percent. This is a 26.81 percent increase over sales of $63.96 million the same period last year.

NYAX

Nayax Q1 EPS $0.19 Beats $0.04 Estimate, Sales $81.11M Miss $85.59M Estimate

LSEA

Landsea Homes shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results. Also the company announced it entered into a definitive agreement to be acquired by New Home.

PLRZ

Polyrizon Launches Preclinical Studies For Intranasal Benzodiazepines Targeting $3.15B Acute Seizure Market

CNSP

CNS Pharmaceuticals shares are trading higher after the company announced the transfer from Cortice Biosciences of Orphan Drug Designation for TPI 287.

Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $55 price target.

XENE

Chardan Capital Maintains Buy on Xenon Pharmaceuticals, Maintains $55 Price Target

Needham analyst Chris Pierce reiterates Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and maintains $13 price target.

ACHR

Needham Reiterates Buy on Archer Aviation, Maintains $13 Price Target

ARWR

Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

"We are excited about the opportunites we're seeing across our business and look forward to driving further revenue growth and value for our shareholders in 2025. We continue to expect full year 2025 GAAP EPS to exceed $2.40 per diluted share, and full year 2025 non-GAAP adjusted EPS to exceed $2.80 per diluted share," Mr. Suzuki concluded.

Guidance

BKTI

CORRECTION: BK Technologies Affirm FY25 GAAP EPS Outlook Of More Than $2.40

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) with a Buy and lowers the price target from $50 to $45.

NGNE

HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $45

MVST

Microvast Holdings shares are trading higher after the company reported better-than-expected Q1 sales results.

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

Health Care

Press Releases

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

General

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Comments

Lyell Immunopharma

Lyell Immunopharma (LYEL) Options

Lyell Immunopharma (NASDAQ:LYEL) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL